



INVEST LIKE A PRO, WITH THE PROS!



Good morning.



Marc Lustig is smiling for a reason.

Watch our [Legalization Live](#) special to see him explain how **CannaRoyalty (CSE:CRZ)**, the company he founded, has become one of the largest distributors in the huge California cannabis market.

Bruce Campbell, portfolio manager of the **StoneCastle Cannabis Growth Fund**, gives you **five cannabis stock ideas** – for free.

And *Valens GroWorks' (CSE:VGW)* CEO Tyler Robson details the company's plan to dominate the extraction business in North America.

Meanwhile, the *new Digest* features research on two, high-quality cannabis names poised to be long-term winners.

Morning Need to Know

Getting you ready for your investing day

October 18, 2018

Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media



CANADIAN ANALYSTS' CALLS

Green Thumb Industries (CSE:GTII). Beacon Securities begins coverage with a "buy" and a price target of \$32 (Canadian).

GMP starts coverage with a "buy" and a \$35 target.

theScore (TSXV:SCR) Mackie Research

maintains a "buy" rating and a price target of \$0.55, giving the stock 77% upside, saying the company is a 2019 story as legalized sports betting increases in the U.S. The sports app company missed quarterly revenue estimates and took a \$2.4 million EBITDA loss.

Fairfax Financial (TSX:FFH) CIBC upgrades to "outperformer" with a target of \$750.

BCE (TSX:BCE). Desjardins upgrades to "buy" and lowers the target to \$59.50 from \$60.75, saying the stock is too cheap to ignore.

Telus (TSX:T). Desjardins moves the target to \$52 from \$43.

Methanex (TSX:MX;NASDAQ:MEOH). CIBC raises the target to \$80 (U.S) from \$75.



U.S. ANALYSTS' CALLS

INITIATIONS

Google (NASDAQ:GOOGL).

Wedbush starts coverage with an "outperform" and a target of \$1,350, implying 20% gains, partly on the stock's "*compelling valuation*".

Nike (NYSE:NKE). Oppenheimer re-starts

coverage with an "outperform" and a price target of \$90, giving the shares 18% upside, saying the company will benefit from its digitally enhanced business model.

**

Mosaic (NYSE:MOS). CIBC ups the target to \$34 from \$31 on higher potash prices.

STOCKS THAT MAY MOVE

Aurora Cannabis (TSX:ACB) will start trading on the New York Stock Exchange on October 23.

MedMen (CSE:MMEN) is selling a significant portion of its real estate to Treehouse REIT for net proceeds of \$12.5 million, and will lease back the properties from Treehouse.

Ericsson (NASDAQ:ERIC). The company's two-year old turnaround continues as quarterly profit beat estimates and sales rose 9% on strength in 5G telecom equipment in North America.

Facebook (NASDAQ:FB). Four large institutional shareholders have proposed to remove founder Mark Zuckerberg as chairman.

Constellation Brands (NYSE:STZ). The man who helped to orchestrate the company's more than \$5 billion investment is Canopy Growth is stepping down as CEO. Ron Sands will become

executive chairman.

Novartis (NYSE:NVS) is buying nuclear medicine specialist Endocyte for \$2.1 billion.

SAP (NYSE:SAP) saw quarterly cloud revenue rise 41% and raised its revenue and profit forecast for the year.

With files from The Globe and Mail, Reuters and Bloomberg News.

MARKETS

TSX and U.S. equity futures are slightly lower with European stock indices mostly higher and Asian indices down overnight.

CURRENCIES

The Canadian dollar is down 0.2% at \$0.7663 U.S.

COMMODITIES

West Texas Intermediate is lower by 1.5% at \$68.73 a barrel (U.S.) after a big build in U.S. weekly inventories.

Gold is up modestly at \$1,228.80 an ounce.

Daily Update

We'll feature a company soon that is completing a reverse takeover and changing its name, and appears to have a lot of potential.

The CEO says the company already has more than 30 hemp-based products on the market in four categories, and is now moving into CBD products.

Access, insight and ideas.

Have a great day!

Mark Bunting
Publisher,
Capital Ideas Media



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply

with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada